← FDA DRUG APPROVALS

FDA BLA · BLA761225

LETYBO

letibotulinumtoxina-wlbg

Sponsor: HUGEL INC

APPLICATION
BLA761225
TYPE
BLA
ORIGINAL APPROVAL
2024-02-29
LATEST ACTION
2024-02-29
ROUTE
INTRAMUSCULAR
DOSAGE FORM
POWDER, FOR SOLUTION
MARKETING STATUS
Prescription

Products

LETYBOPrescription
LETIBOTULINUMTOXINA-WLBG 0.1ML(4UNITS) · POWDER, FOR SOLUTION

Approval history

2024-02-29Type 1 - New Molecular Entity · Original · standardLabelAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Biologics industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →